Premature ovarian insufficiency

Antifibrotic Repurposing: How Finerenone Could Rejuvenate the Ovarian Niche and Restore Fertility in POI

By MedXY 02/07/2026

A breakthrough study in Science reveals that the antifibrotic drug finerenone restores fertility in premature ovarian insufficiency (POI) by reducing ovarian stromal fibrosis, enabling follicle development where hormone therapy previously failed.

Clinical Updates news OB/GYN & Women's Health

Emerging Environmental Threats to Ovarian Reserve: The Association Between Novel PFAS Exposure and Premature Ovarian Insufficiency

By MedXY 12/26/2025

This review synthesizes recent clinical evidence identifying novel per- and poly-fluoroalkyl substances (PFAS) as significant risk factors for premature ovarian insufficiency (POI), highlighting their impact on ovarian reserve markers and endocrine health.

Diabetes & Endocrinology OB/GYN & Women's Health Specialties

Navigating the Frontiers of Premature Ovarian Insufficiency Research: Insights from the Top 100 Influential Articles

By MedXY 10/22/2025

A comprehensive bibliometric analysis of the 100 most-cited articles in premature ovarian insufficiency reveals key research trends, leading contributors, and emerging scientific directions in genetics, cardiovascular disease, and immunology.